Scientists, despite their best efforts, have not been able to identify a way to inhibit the oncoprotein Myc. Uropathogenic Escherichia coli, though, has apparently figured it out.
RNA has “huge potential” as a therapeutic modality and is beginning to deliver on that potential. But “manufacturing RNA has issues in production, delivery and performance,” Thomas Barnes told BioWorld. Barnes is the CEO of startup Orna Therapeutics LLC, which has the goal of addressing those issues with oRNA, an engineered form of circular RNA.
Keeping you up to date on recent developments in oncology, including: MR touted as potential screening modality for prostate cancer; Classifying variants of unknown significance; Tumor neoantigens can inhibit immune response; MEK perhaps a useful target in some bladder cancers.
BioWorld looks at translational medicine, including: Classifying variants of unknown significance; Platelets release antigenic DNA in lupus; Intracranial samples give glimpse into stroke response.
BioWorld looks at translational medicine, including: Metabolic changes are antibiotic resistance mechanism; Tumor neoantigens can inhibit immune response; Chromosome organization machinery linked to DNA repair.
Keeping you up to date on recent developments in oncology, including: CD161 identified as impediment to immune response in diffuse glioma; iPSCs give sneak preview of AML; A role for chloroquine in cancer; Fecal transplant may aid in response to immunotherapy in melanoma.
Researchers at Hannover Medical School have developed an organoid that mimicked the early codevelopment of the heart with liver, lung and blood vessels.
